Staidson BioPharm(SZ:300204) Xin Lang Cai Jing·2025-11-13 05:22Core Insights - Shuyou Shen's stock price increased by 5.08% on November 13, reaching 39.12 CNY per share, with a trading volume of 1.698 billion CNY and a turnover rate of 10.05%, resulting in a total market capitalization of 18.69 billion CNY [1] - The stock has risen for three consecutive days, with a cumulative increase of 9.56% during this period [1] Company Overview - Shuyou Shen (Beijing) Biopharmaceutical Co., Ltd. was established on August 16, 2002, and went public on April 15, 2011 [1] - The company primarily engages in the research, production, and sales of biological products and some chemical drugs [1] - Main revenue sources include: 59.17% from injectable mouse nerve growth factor (Sutai Shen), 33.19% from compound polyethylene glycol electrolyte powder, and 7.63% from other products [1] Fund Holdings - CITIC Prudential Fund holds a significant position in Shuyou Shen, with the CITIC Prudential Zhi Rui Mixed A Fund (003432) owning 295,000 shares, accounting for 3.99% of the fund's net value, making it the eighth-largest holding [2] - The fund has realized a floating profit of approximately 557,600 CNY today and 958,800 CNY during the three-day increase [2] Fund Manager Performance - The fund manager Wang Rui has a tenure of 10 years and 201 days, with a total fund size of 6.438 billion CNY and a best return of 253.09% during his tenure [3] - Liu Hongliang has been managing the fund for 1 year and 121 days, with a fund size of 2.693 billion CNY and a best return of 9.67% [3] - Zhu Huiling has a shorter tenure of 226 days, managing a fund size of 259 million CNY, with a best return of 8.63% [3]